The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2

Oncotarget

Volumn 6, Issue 4, 2015, Pages 2397-2406

  Gu, Yunyan ^a   Zhang, Mengmeng ^a   Peng, Fuduan ^a   Fang, Lei ^c   Zhang, Yuanyuan ^a   Liang, Haihai ^a   Zhou, Wenbin ^a   Ao, Lu ^a,b   Guo, Zheng ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

BRCA1; BRCA2; miRNAs; Ovarian cancer; Prognosis

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MICRORNA; MICRORNA 146A; MICRORNA 148A; MICRORNA 545; PLATINUM COMPLEX; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MIR545 MICRORNA, HUMAN; MIRN146 MICRORNA, HUMAN; MIRN148 MICRORNA, HUMAN; PLATINUM;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; WILD TYPE; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; BRCA2 PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PLATINUM; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84923008669     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2963     Document Type: Article

References (41)

1. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM and Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA. 2012; 109(10):3921-3926.
2. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-615.
3. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300.
4. Ow GS, Ivshina AV, Fuentes G and Kuznetsov VA. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures. Cell Cycle. 2014; 13(14):2262-2280.
5. Cooke SL and Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 2011; 12(12):1169-1174.
6. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366(15):1382-1392.
7. Roy R, Chun J and Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2012; 12(1):68-78.
8. Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients-a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). Eur J Cancer. 2014; 50(12):2090-2098.
9. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012; 307(4):382-390.
10. Soegaard M, Kjaer SK, Cox M, Wozniak E, Hogdall E, Hogdall C, Blaakaer J, Jacobs IJ, Gayther SA and Ramus SJ. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res. 2008; 14(12):3761-3767.
11. McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P and Narod SA. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst. 2013; 105(2):141-148.
12. Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, Goff BA and Welcsh P. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer. 2009; 8:48.
13. Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B and Reich R. miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med. 2011; 15(7):1593-1602.
14. Montagner S, Orlandi EM, Merante S and Monticelli S. The role of miRNAs in mast cells and other innate immune cells. Immunol Rev. 2013; 253(1):12-24.
15. Guan Y, Yao H, Zheng Z, Qiu G and Sun K. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer. 2011; 128(10):2274-2283.
16. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011; 17(2):211-215.
17. Garofalo M and Croce CM. microRNAs: Master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol. 2011; 51:25-43.
18. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Fuso Nerini I, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol. 2011; 12(3):273-285.
19. Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, Martinez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D and Rodriguez-Antona C. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients. Endocr Relat Cancer. 2011; 18(1):85-95.
20. Wang X, Meng X, Li H, Liu W, Shen S and Gao Z. MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer. Clin Transl Oncol. 2014; 16(11):954-958.
21. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM, Gorospe M, Harris AL, Helleday T, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011; 41(2):210-220.
22. Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X, Ma D, Zhou J and Chen G. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl Cancer Inst. 2013; 105(22):1750-1758.
23. Kang J, D'Andrea AD and Kozono D. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J Natl Cancer Inst. 2012; 104(9):670-681.
24. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, Lidereau R, Mikaelian I and Mazoyer S. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011; 3(5):279-290.
25. Dimitrov SD, Lu D, Naetar N, Hu Y, Pathania S, Kanellopoulou C and Livingston DM. Physiological modulation of endogenous BRCA1 p220 abundance suppresses DNA damage during the cell cycle. Genes Dev. 2013; 27(20):2274-2291.
26. Mercer TR, Dinger ME and Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009; 10(3):155-159.
27. Qi P and Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol. 2013; 26(2):155-165.
28. Zhang XQ, Sun S, Lam KF, Kiang KM, Pu JK, Ho AS, Lui WM, Fung CF, Wong TS and Leung GK. A long non-coding RNA signature in glioblastoma multiforme predicts survival. Neurobiol Dis. 2013; 58:123-131.
29. Gu Y, Wang H, Qin Y, Zhang Y, Zhao W, Qi L, Wang C and Guo Z. Network analysis of genomic alteration profiles reveals co-altered functional modules and driver genes for glioblastoma. Mol Biosyst. 2013; 9(3):467-477.
30. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK and Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011; 306(14):1557-1565.
31. Lewis BP, Burge CB and Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20.
32. Betel D, Koppal A, Agius P, Sander C and Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 2010; 11(8):R90.
33. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M and Rajewsky N. Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500.
34. Kozomara A and Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011; 39(Database issue):D152-157.
35. Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, Filippidis C, Dalamagas T and Hatzigeorgiou AG. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 2013; 41(Web Server issue):W169-173.
36. Kertesz M, Iovino N, Unnerstall U, Gaul U and Segal E. The role of site accessibility in microRNA target recognition. Nat Genet. 2007; 39(10):1278-1284.
37. Hsu SD, Chu CH, Tsou AP, Chen SJ, Chen HC, Hsu PW, Wong YH, Chen YH, Chen GH and Huang HD. miRNAMap 2.0: genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res. 2008; 36(Database issue):D165-169.
38. Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM, Chien CH, Wu MC, Huang CY, et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011; 39(Database issue):D163-169.
39. Xiao F, Zuo Z, Cai G, Kang S, Gao X and Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009; 37(Database issue):D105-110.
40. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25(1):25-29.
41. Hong G, Zhang W, Li H, Shen X and Guo Z. Separate enrichment analysis of pathways for up-and downregulated genes. J R Soc Interface. 2014; 11(92):20130950.